Literature DB >> 25077350

Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies.

J Costa-Pinto, A Pérez-Rodríguez, M del C Goméz-del-Castillo, E Lourés, A Rodríguez-Trillo, J Batlle, M F López-Fernández.   

Abstract

Diagnostics of von Willebrand disease (VWD) includes assessment of factor VIII (FVIII) coagulant activity, von Willebrand factor (VWF) antigen (VWF:Ag) and VWF ristocetin cofactor activity (VWF:RCo), and more specific tests as multimeric and genetic analyses are necessary for the correct VWD classification. The ACL AcuStar analyzer introduces chemiluminescence (CL) technology in detection of VWD with automated VWF:Ag and VWF:RCo assays. Compare VWF:Ag-ELISA and VWF:RCo by aggregometry conventional assays with new CL VWF:Ag-IL and VWF:RCo-IL assays, investigate the ability to make accurate VWD diagnosis and concordance with multimeric and genetic analyses. 146 patients with congenital VWD (51 Type 1; 34 Type 2A; 16 Type 2B; 31 Type 2M; 5 Type 2N; 9 Type 3) and 30 healthy normal subjects were included. A comparison was made between CL and conventional methods. Diagnostic evaluation included: VWF:RCo/VWF:Ag ratio, multimeric distribution (sodium dodecyl sulfate [SDS]-agarose gel) of VWF and genetic analysis in 110 of 146 patients. CL and conventional methods revealed good correlation. Kappa test agreement diagnosis was >0.8. CL diagnostic sensitivity was 100% and specificity 97%. Multimeric and genetic analysis were of help in clarifying 13 discrepancies of diagnosis between methods, of which six discrepancies were explained by lack of conventional methods′ sensibility. CL methodology can detect VWD and discriminate between type 1, 3 and variant forms and offers an automated, faster, sensitive and less cumbersome method when compared to conventional assays, in particular VWF:RCo by aggregometry. In some cases, even with all phenotype and genetic analyses, discrepancies exist in the classification of VWD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25077350     DOI: 10.1111/hae.12380

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

2.  The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.

Authors:  Amihai Rottenstreich; Geffen Kleinstern; Hagai Amsalem; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 3.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

Review 4.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

5.  Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers.

Authors:  Attila Szederjesi; Luciano Baronciani; Ulrich Budde; Giancarlo Castaman; Paola Colpani; Andrew S Lawrie; Yuan Liu; Robert Montgomery; Flora Peyvandi; Reinhard Schneppenheim; Jürgen Patzke; Imre Bodó
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

6.  An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Authors:  A Szederjesi; L Baronciani; U Budde; G Castaman; A S Lawrie; Y Liu; R Montgomery; F Peyvandi; R Schneppenheim; A Várkonyi; J Patzke; I Bodó
Journal:  J Thromb Haemost       Date:  2018-06-13       Impact factor: 5.824

7.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

8.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28

9.  Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Authors:  Almudena Pérez-Rodríguez; Javier Batlle; Irene Corrales; Nina Borràs; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Nira Navarro; Carmen Altisent; Rocío Pérez-Montes; Shally Marcellini; Ana Moreto; Sonia Herrero; Inmaculada Soto; Nuria Fernández Mosteirín; Víctor Jiménez-Yuste; Nieves Alonso; Aurora de Andrés Jacob; Emilia Fontanes; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Nerea Castro Quismondo; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Maria Tenorio; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Manuela Dobón; Carlos Aguilar; Fernando Batlle; Francisco Vidal; María Fernanda López-Fernández
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

10.  The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms.

Authors:  Monica Sacco; Stefano Lancellotti; Alessio Branchini; Maira Tardugno; Maria Francesca Testa; Barbara Lunghi; Francesco Bernardi; Mirko Pinotti; Betti Giusti; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  J Thromb Haemost       Date:  2022-06-09       Impact factor: 16.036

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.